Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

FDA reviews preliminary data from SCOUT safety study of Meridia

Nov. 26, 2009

Novel dipeptidyl peptidase-IV inhibitors in early development at Sun Pharma

Nov. 26, 2009

Cytopia begins enrollment in phase I/II trial of CYT-387 in myelofibrosis

Nov. 26, 2009

Aleglitazar has no clinically relevant interactions with statins in healthy subjects

Nov. 26, 2009

Phase III data support benefit of mipomersen in homozygous familiar hypercholesterolemia

Nov. 26, 2009

Gilead identifies SCD inhibitors for the treatment of diabetes

Nov. 25, 2009

Shire submits MAA to EMEA for velaglucerase alfa for type 1 Gaucher disease

Nov. 25, 2009

KineMed receives grant from Daiichi Sankyo for clinical Welchol trial in diabetes type 2

Nov. 24, 2009

Raptor completes phase II trial of delayed-release cysteamine in cystinosis

Nov. 24, 2009

GFT-505 meets all primary endpoints in phase II trial in prediabetic patients

Nov. 24, 2009

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 12, 2026
Alzheimer’s, beyond the brain
BioWorld
Researchers at Daping Hospital in China have reported that liver-targeted delivery of the APOE3-Christchurch (APOE3Ch) variant, a rare protective form of...
New assay for drug discovery against chemo-induced peripheral neuropathy
BioWorld Science
A group led by researchers at Boston Children’s Hospital established a scalable and reproducible model of paclitaxel-induced axon degeneration and neurotoxicity...
First cruise ship hantavirus genome points to zoonotic spillover
BioWorld
The initial appraisal of the first complete genome sequence of a hantavirus isolated from a patient in Switzerland who was a passenger on the cruise ship MV...